The VESALIUS-CV study presented at ESC Congress 2026 reveals that evolocumab lowers the risk of death by 20% i! Swipe to see →
The cardiovascular treatment landscape has reached a historic milestone with the release of compelling data from the Phase 3 VESALIUS-CV ...
Evolocumab operates through a highly sophisticated and targeted biological mechanism by directly inhibiting the PCSK9 protein in the huma...
The VESALIUS-CV trial was meticulously designed to evaluate long-term clinical outcomes in a population frequently overlooked by traditio...
To fully comprehend the clinical advantage provided by evolocumab, it is absolutely essential to compare it directly with traditional the...
The foundational paradigm of modern preventive cardiology is rapidly shifting toward much earlier and significantly more assertive medica...
The stunning revelations from the ESC 2026 Congress will undoubtedly resonate through official medical guidelines for the next decade. Wi...
Visit our portal and read the full story!